+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Management of Clinical Stage I Nonseminomatous Germ Cell Testicular Tumors: A 25-year Single-center Experience



Management of Clinical Stage I Nonseminomatous Germ Cell Testicular Tumors: A 25-year Single-center Experience



Clinical Genitourinary Cancer 15(6): E1015-E1019



Surveillance after orchiectomy alone has become popular in the management of clinical stage I nonseminomatous germ cell testicular tumors (CSI NSGCTT). Efforts to identify patients at high risk of disease progression led to a search for risk factors in CSI NSGCTT. The aim of this study was to analyze a 25-year single-center experience with risk-adapted therapeutic approaches-active surveillance (AS) versus adjuvant chemotherapy (ACT). From January 1992 to January 2017, a total of 485 patients with CSI NSGCTT were stratified into the AS group (low-risk patients) and the ACT group (high-risk patients). Differences between relapse rates and overall survival rates in these groups were statistically analyzed. In the AS group, relapse occurred in 52 (17.3%) of 301 patients with a median follow-up of 7.2 months (range, 2-86 months). Six (2.0%) patients of this group died, with a median follow-up of 34.3 months (range, 11-102 months). In the ACT group, relapse occurred in 2 (1.1%) of 184 patients with a median follow-up of 56.2 months (range, 42-70 months). One (0.54%) patient died at 139.4 months following orchiectomy. The relapse rate for the AS group was 16.7 times higher than that for the ACT group. The groups did not differ in overall survival. The 3-year overall survival of all patients with CSI NSGCTT was 99.1% (95% confidence interval, 97.7%-99.7%). Three of a total of 7 deaths occurred thereafter. The policy of AS is recommended only in patients with low-risk CSI NSGCTT.

(PDF emailed within 0-6 h: $19.90)

Accession: 059940702

Download citation: RISBibTeXText

PMID: 28673797

DOI: 10.1016/j.clgc.2017.05.023


Related references

Detection of recurrence in patients with clinical stage I nonseminomatous testicular germ cell tumors and consequences for further follow-up: a single-center 10-year experience. Journal of Clinical Oncology 13(5): 1188-1194, 1995

Late relapse after treatment for nonseminomatous testicular germ cell tumors according to a single center-based experience. World Journal of Urology 22(1): 55-59, 2004

Management of patients with clinical stage I nonseminomatous germ cell testicular cancer: Active surveillance versus adjuvant chemotherapy - single-centre experience. Neoplasma 62(1): 159-163, 2014

Management and outcome of bilateral testicular germ cell tumors: a 25-year single center experience. International Journal of Urology 15(9): 821-826, 2008

Five years experience with orchiectomy alone surveillance for clinical stage i nonseminomatous germ cell testicular tumors. Journal of Urology 137(4 PART 2): 211A, 1987

The management of stage I nonseminomatous testicular germ cell tumors. Oncology 71(3-4): 151-158, 2007

Retroperitoneal lymph node dissection in clinical stage I non-seminomatous germ cell testicular tumours Long term results in a single-center 16-year experience. European Urology Supplements 1(1): 94, 2002

Stage II nonseminomatous germ-cell testicular tumors: The Indiana experience and risk-benefit analysis. World Journal of Urology 12(3): 143-147, 1994

New prognostic parameters to predict pathological stage in clinical stage A nonseminomatous testicular germ cell tumors. Journal of Urology 153(4 SUPPL ): 244A, 1995

Tumor proliferative activity is predictive of pathological stage in clinical stage A nonseminomatous testicular germ cell tumors. Journal of Urology 155(2): 579-586, 1996

The value of prognostic factors in the management of stage I nonseminomatous germ cell testicular tumors (NSGCTT). Neoplasma 43(3): 195-197, 1996

Nonseminomatous germ cell testicular tumors clinical stage I A retrospective analysis. EJC Supplements 1(5): S271, 2003

Surveillance for patients with clinical stage I nonseminomatous testicular germ cell tumors. World Journal of Urology 33(9): 1351-1357, 2016

Clinical evaluation of surgical stage I and IIA nonseminomatous testicular germ cell tumors. Nihon Hinyokika Gakkai Zasshi. Japanese Journal of Urology 78(6): 1060-1064, 1987

Cytogenetic abnormalities and clinical stage in testicular nonseminomatous germ cell tumors. Cancer Genetics & Cytogenetics. 70(1): 12-16, 1993